CLDI · Calidi Biotherapeutics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“The Company estimates that based on the Company's liquidity resources, there is substantial doubt about the Company's ability to continue as a going concern within 12 months from the date of issuance of these unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 13, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jul 31, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Jul 31, 2026.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLDI
this stock
Calidi Biotherapeutics, Inc.
|
$3.20M | — | — | — | 8.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.64B | +13.7% | +46.2% | 30.0 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.46B | +1.2% | +20.8% | 19.4 | 2.5% |
|
ARGX
Argenx SE
|
$61.22B | +17.1% | — | — | 2.0% |
|
MRNA
Moderna, Inc.
|
$57.48B | +388.2% | +4.3% | — | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jul 31, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLDI | -8.2% | -19.5% | — | -7.5% | — |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -7.0% | -17.7% | — | -7.1% | — |